What is Novaerus?
Novaerus is at the forefront of addressing indoor air quality challenges through its innovative medical-grade air purification solutions. The company's patented NanoStrike technology is engineered for continuous air disinfection, effectively neutralizing airborne threats such as viruses, bacteria, and allergens. This makes Novaerus devices particularly vital for high-risk environments, including hospitals, schools, and dental clinics, where maintaining stringent air safety standards is paramount. Their product line, featuring devices like the Defend 400 and Defend 1050, offers portable and accessible solutions designed to enhance safety and promote healthier air environments across various institutional and commercial settings.
How much funding has Novaerus raised?
Novaerus has raised a total of $10M across 1 funding round:
Private Equity
$10M
Private Equity (2014): $10M with participation from Polaris Partners
Key Investors in Novaerus
Polaris Partners
Polaris Partners is a venture capital firm with a strong focus on backing transformative companies within the biotech and healthcare industries. They are known for their hands-on approach, providing entrepreneurs with strategic guidance and resources to foster innovation and drive growth.
What's next for Novaerus?
The recent major strategic investment in Novaerus signals a strong validation of its technology and market position. This capital infusion is expected to fuel further expansion, likely focusing on scaling production, enhancing research and development for next-generation air purification systems, and broadening its market reach into new geographical regions and industry verticals. The company's focus on critical environments suggests a strategic emphasis on partnerships with healthcare networks and educational institutions, positioning Novaerus to capitalize on the increasing global demand for advanced air safety solutions.
See full Novaerus company page
